Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study - Concepedia

Concepedia

Publication | Closed Access

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study

527

Citations

25

References

2012

Year

Kjell Magne Tveit, Tormod Kyrre Guren, Bengt Glimelius, Per Pfeiffer, Halfdan Sørbye, Seppo Pyrhönen, Fridbjörn Sigurdsson, Elin H. Kure, Tone Ikdahl, Eva Skovlund,

Journal of Clinical Oncology

Abstract

Cetuximab did not add significant benefit to the Nordic FLOX regimen in first-line treatment of mCRC.

References

	Year	Citations

Page 1